Editorial
When should ACE inhibitors or warfarin be discontinued after myocardial infarction?
| The first 150 words of the full text of this article appear below. |
In
the current climate of cost containment, discontinuation of medications
shown to have efficacy has taken on an urgency that may not appear
appropriate to the individual clinician when applied to the individual
patient. However, it is often in the patient's best interest to
decrease the number of medications prescribed. Following a myocardial
infarction, patients are usually discharged on multiple medications
including
adrenergic receptor blockers, angiotensin converting
enzyme (ACE) inhibitors, aspirin, and lipid lowering agents.
Polypharmacy is a national health issue that increases the risk of
medication errors in formulation or dosage by the prescriber, the
pharmacist or the patient, and increases the likelihood of drug
interaction. Polypharmacy also decreases patient compliance with the
medical regimen.1 2 Cost is a factor for many patients
and one that may be underappreciated by physicians. In addition, no
drug is without side effects. Discontinuation of a medication removes
the possibility of untoward side effects,
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
